Form 4: Cardiff Oncology CEO Mani Mohindru Receives Stock Options
Statement of Changes in Beneficial Ownership
Cardiff Oncology CEO Mani Mohindru was granted 600,000 stock options with an exercise price of $1.62.
Summary
- CEO Mani Mohindru acquired 600,000 stock options in Cardiff Oncology, Inc. (CRDF).
- The options have an exercise price of $1.62 per share.
- The grant date for the transaction is March 31, 2026.
- The options expire on March 31, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of these options.
Risks
- Market volatility affecting the value of equity-based compensation.
- Dependence on the company's ability to achieve clinical milestones to justify the exercise price.
Future Outlook
The options vest over a four-year period, with 150,000 vesting on March 31, 2027, and the remainder vesting in 36 equal monthly installments thereafter, indicating a long-term retention strategy.
Industry Context
StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for aligning leadership with long-term clinical development goals and retention.
Comparison to Industry Standards
- The vesting schedule of 1 year cliff followed by monthly vesting is consistent with standard industry practices for executive compensation in small-cap biotech firms.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of 150,000 options on March 31, 2027.
- Commencement of monthly vesting for remaining options starting April 2027.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of the stock option grant transaction. |
| 03/31/2027 | Initial vesting date for the first 150,000 options. |
| 04/02/2026 | Date the Form 4 was signed and filed. |
| 03/31/2036 | Expiration date of the granted stock options. |
Keywords
Cardiff Oncology, CRDF, Insider Trading, Stock Options, Executive Compensation, Mani Mohindru
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.